3
Indication details
- Combined Agent(s)
- Best supportive care
- Control Arm
- Placebo + best supportive care
- Therapeutic Indication
- Fruquintinib for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, if RAS wild-type and medically appropriate, an anti-EGFR therapy, and at least one of trifluridine/tipiracil or regorafenib.
- Tumour Type
-
Gastrointestinal Cancers
- Tumour Sub-type
- Colorectal Cancer
- Tumour Stage
- Metastatic
- Trial Name
- FRESCO -2
- NCT Number
- NCT04322539
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval November 2023
- EMA Approval
- EMA (CHMP) April 2024. EC decision June 2024
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- OS Control
- 4.8 months
- OS Gain
- 2.6 months
- OS HR
- 0.66 (0.55 - 0.80)
Adjustments
- QoL Comment
-
QoL data pending
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 412
- Scorecard version
- 1
- Issue date
- 04.12.2023